A physiologically-based pharmacokinetic(PB-PK) model for ethylene dibromide: Relevance of extrahepatic metabolism

Food and Chemical Toxicology

Volumn 38, Issue 8, 2000, Pages 707-716

  Hissink, A M ^a   Wormhoudt, L W ^b   Sherratt, P J ^c   Hayes, J D ^c   Commandeur, J N M ^b   Vermeulen, N P E ^b   Van Bladeren, P J ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Ethylene dibromide; Extrapolation; Glutathione S transferase; Interindividual variation; PBPK; Risk assessment

Indexed keywords

1,2 DIBROMOETHANE; CYTOCHROME P450; GLUTATHIONE; GLUTATHIONE TRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; MALE; NONHUMAN; PHARMACOKINETICS; PREDICTION; RAT; RISK ASSESSMENT; TOXICITY TESTING; XENOBIOTIC METABOLISM;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOTRANSFORMATION; CHROMATOGRAPHY, GAS; CYTOCHROME P-450 ENZYME SYSTEM; ETHYLENE DIBROMIDE; GLUTATHIONE TRANSFERASE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; MODELS, BIOLOGICAL; RATS; RATS, WISTAR; RISK ASSESSMENT;

EID: 0033923457     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(00)00059-4     Document Type: Article

References (48)

1. Allen B.C., Covington T.R., Clewell H.J. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology. 111:1996;289-303.
2. Andersen M.E., Clewell H.J.III, Gargas M.L, Smith F.A., Reitz R.H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicology and Applied Pharmacology. 87:1987;185-205.
3. Andersen M.E., Clewell H.J.III, Frederick C.B. Contemporary issues in toxicology. Applying simulation modeling to problems in toxicology and risk assessment - a short perspective. Toxicology and Applied Pharmacology. 133:1995;181-187.
4. Arms A. D. and Travis C. C. (1988) Reference physiological parameters in pharmacokinetic modeling. Office of Health and Environmental Assessment. US EPA Washington, DC. NTIS PB88-196019.
5. Awasthi Y.C., Sharma R., Singhal S.S. Human glutathione S-transferases. International Journal of Biochemistry. 26:1994;295-308.
6. Bogaards J.J.P., Van Ommen B., Van Bladeren P.J. An improved method for the separation and quantification of glutathione S-transferase subunits in rat tissue using high-performance liquid chromatography. Journal of Chromatography. 474:1989;435-440.
7. Clewell H.J.III The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. Toxicology Letters. 79:1995;207-217.
8. Clewell H.J., Andersen M.E. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology. 111:1996;315-329.
9. Corrigall A.V., Kirsch R. Glutathione S-transferase distribution and concentration in human organs. Biochemical International. 16:1988;443-448.
10. Dallas C.E., Chen X.M., Muralidhara S., Varkonyi P., Tackett R.L., Bruckner J.V. Physiologically based pharmacokinetic model useful in prediction of the influence of species, dose, and exposure route on perchloroethylene pharmacokinetics. Journal of Toxicology and Environmental Health. 44:1995;301-317.
11. Davies B., Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research. 10:1993;1093-1095.
12. De Waziers I., Cugnenc P.H., Yang C.S., Leroux J.P., Beaune P.H. Cytochrome P450 enzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. Journal of Pharmacology and Experimental Therapeutics. 253:1990;387-394.
13. Goasduff T., Bellec G., Amet Y., Dreano Y., Menez J., Berthou F. P450 2E1 expression in liver, kidney, and lung of rats treated with single or combined inducers. Alcohol. 13:1996;301-308.
14. Guengerich F.P., Thier R., Persmark M., Taylor J.B., Pemble S.E., Ketterer B. Conjugation of carcinogens by theta class glutathione s-transferases. mechanisms and relevance to variations in human risk Pharmacogenetics. 5:1995;103-107.
15. Hattis D. Human interindividual variability in susceptibility to toxic effects. From annoying detail to a central determinant of risk Toxicology. 111:1996;5-14.
16. Hayes K.A., Brennan B., Chenery R., Houston B. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metabolism and Disposition. 23:1995;349-353.
17. Hayes J.D., Mantle T.J. Use of immuno-blot techniques to discriminate between the glutathione S-transferase Yf, Yk, Ya, Yn/Yb and Yc subunits and to study their distribution in extrahepatic tissues. Biochemical Journal. 233:1986;779-788.
18. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family. Regulation of GST and the contribution of the enzymes to cancer chemoprotection and drug resistance Critical Reviews in Biochemistry and Molecular Biology. 30:1995;445-600.
19. Hissink A.M., van Ommen B., Krüse J., van Bladeren P.J. A physiologically based pharmacokinetic (PB-PK) model for 1,2-dichlorobenzene linked to two possible parameters of toxicity. Toxicology and Applied Pharmacology. 145:1997;301-310.
20. Hoener B. Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharmaceutics and Drug Disposition. 15:1994;295-304.
21. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology. 47:1994;1469-1479.
22. Huff J.E. 1,2-Dibromoethane (ethylene dibromide). Environmental Health Perspectives. 47:1983;359-363.
23. ICRP (1975) International Commission on Radiological Protection- Report of the task group on Reference Man, ICRP No. 23, Pergamon Press, London.
24. Juronen E., Tasa G., Uusküla M., Pooga M., Mikelsaar A. Purification, characterization and tissue distribution of human class theta glutathione S-transferase T1-1. Biochemistry and Molecular Biology International. 39:1996;21-29.
25. Kedderis G.L., Carfagna M.A., Held S.D., Batra R., Murphy J.E., Gargas M.L. Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. Toxicology and Applied Pharmacology. 123:1993;274-282.
26. 7-guanyl)ethyl]glutathione, the major DNA adduct formed from 1,2-dibromoethane. Biochemistry. 25:1986;2191-2198.
27. Krishnan K., Gargas M.L., Fennell T.R., Andersen M.E. A physiologically based description of ethylene oxide dosimetry in the rat. Toxicology and Industrial Health. 8:1992;121-140.
28. Leung H.W., Paustenbach D.J. Physiologically based pharmacokinetic and pharmacodynamic modeling in health risk assessment and characterization of hazardous substances. Toxicology Letters. 79:1995;55-65.
29. Lipscomb J.C., Garrett C.M., Snawder J.E. Cytochrome P450-dependent metabolism of trichloroethylene. interindividual differences in humans Toxicology and Applied Pharmacology. 142:1997;311-318.
30. MacFarland R.T., Gandolfi A.J., Sipes I.G. Extra-hepatic GSH-dependent metabolism of 1,2-dibromoethane (DBE) and 1,2-dibromo-3-chloropropane (DBCP) in the rat and mouse. Drug and Chemical Toxicology. 7:1984;213-227.
31. Meyer D.J., Harris J.M., Gilmore K.S., Coles B., Kensler T.W., Ketterer B. Quantitation of tissue- and sex-specific induction of rat GSH transferase subunits by dietary 1,2-dithiole-3-thiones. Carcinogenesis. 14:1993;567-572.
32. NTP (1982) Carcinogenesis bioassay of 1,2-dibromoethane in F344 rats and B6C3F1 mice (Inhalation study). National Toxicology Program. Natl. Inst. Hlth Publ. No. 82-1766, pp. 1-163.
33. Olson W.A., Habermann R.T., Weisburger E.K., Ward J.M., Weisburger J.H. Induction of stomach cancer in rats and mice by halogenated aliphatic fumigants. Journal of National Cancer Institute. 51:1973;1993-1995.
34. Ploemen J.H.T.M., Wormhoudt L.W., Haenen G.R.M.M., Oudshoorn M.J., Commandeur J.N.M., Vermeulen N.P.E., De Waziers I., Beaune P.H., Watabe T., Van Bladeren P.J. The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds. the case of ethylene dibromide Toxicology and Applied Pharmacology. 143:1997;56-69.
35. Ploemen J.H.T.M., Wormhoud L.W., Van Ommen B., Commandeur J.N.M., Vermeulen N.P.E., Van Bladeren P.J. Polymorphism in the glutathione conjugation activity of human erythrocytes towards ethylene dibromide and 1,2-epoxy-3-(p-nitrophenoxy)-propane. Biochimica et Biophysica Acta. 1243:1995;469-476.
36. Ramsey J.C., Park C.N., Ott M.G., Gehring P.J. Carcinogenic risk assessment. ethylene dibromide Toxicology ad Applied Phrmacology. 47:1978;411-414.
37. Roberts B.J., Shoaf S.E., Jeong K., Song B.J. Induction of CYP2E1 in liver, kidney, brain and intestine during chronic ethanol administration and withdrawal. evidence that CYP2E1 possesses a rapid phase half-life of 6 hours or less Biochemical and Biophysical Research Communications. 205:1994;1064-1071.
38. Roth W.L., Freeman R.A., Wilson A.G.E. A physiologically based model for gastrointestinal absorption and excretion of chemicals carried by lipids. Risk Analysis. 13:1993;531-543.
39. Rowe J.D., Nieves E., Listowsky I. Subunit diversity and tissue distribution of human glutathione S-transferases. interpretations based on electrospray ionization-MS and peptide sequence-specific antisera Biochemical Journal. 325:1997;481-486.
40. Sherratt P.J., Pulford D.J., Harrison D.J., Green T., Hayes J.D. Evidence that human class Theta glutathione S-transferase T1-1 can catalyse the activation of dichloromethane, a liver and lung carcinogen in the mouse. Comparison of the tissue distribution of GSTT1-1 with that of class Alpha, Mu, and Pi GST in human. Biochemical Journal. 326:1997;837-846.
41. Shimada T., Yamazaki H., Mimura M., Wakamiya N., Ueng Y., Guengerich F.P., Inui Y. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs. Drug Metabolism and Disposition. 24:1996;515-522.
42. Smith G., Stanley L.A., Sim E., Strange R.C., Wolf C.R. Metabolic polymorphisms and cancer susceptibility. Cancer Surveys. 25:1995;27-65.
43. Van Bladeren P.J., Breimer D.D., van Huijgevoort J.A.T.C.M., Vermeulen N.P.E., van der Gen A. The metabolic formation of N-acetyl-S-2-hydroxyethyl-L-cysteine from tetradeutero-1,2-dibromoethane. Relative importance of oxidation and glutathione conjugation in vivo. Biochemical Pharmacology. 30:1981;2499-2502.
44. Van Duuren B.L., Goldschmidt B.M., Loewengart G., Smith A.C., Melchionne S., Seldman I., Roth D. Carcinogenicity of halogenated olefinic and aliphatic hydrocarbons in mice. Journal of the National Cancer Institute. 63:1979;1433-1439.
45. Van Duuren B.L., Seidman I., Melchionne S., Kline S.A. Carcinogenicity bioassays of bromoacetaldehyde and bromoethanol. potential metabolites of dibromoethane Teratogenesis, Carcinogenesis and Mutagenesis. 5:1985;393-403.
46. Weisburger E.K. Carcinogenicity studies on halogenated hydrocarbons. Environmental Health Perspectives. 21:1977;7-16.
47. Wormhoudt L.W., Commandeur J.N.M., Ploemen J.H.T.M., Abdoelgafoer R.S., Makansi A., van Bladeren P.J., Vermeulen N.P.E. Urinary thiodiacetic acid. A selective biomarker for the cytochrome P450-catalyzed oxidation of 1,2-dibromoethane in the rat. Drug Metabolism and Disposition. 25:1997;508-515.
48. 14C]-dibromoethane in male wistar rats. Drug Metabolism and Disposition. 26:1998;437-447.